更新于：2024-06-25
MK-8189
更新于：2024-06-25
概要
基本信息
非在研机构 |
最高研发阶段临床2期 |
首次获批日期- |
最高研发阶段(中国)无进展 |
特殊审评- |
结构
分子式C19H22N6OS |
InChIKeyWQKPZDLZRFTMTI-CABCVRRESA-N |
CAS号1424371-93-6 |
关联
12
项与 MK-8189 相关的临床试验A Multiple Dose Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-8189 in Participants With Bipolar I Disorder
The goal of this study is to evaluate the safety and tolerability of MK-8189 in participants with stable bipolar I disorder. There will be no hypothesis testing in this study.
开始日期2024-04-08 |
申办/合作机构 |
A Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the Long-Acting Injectable of MK-5720 in Participants With Schizophrenia
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of single ascending intramuscular doses of MK-5720, and the safety and tolerability of multiple once-daily oral doses of MK-8189, in participants with schizophrenia. The primary study hypothesis is that the administration of MK-5720 is safe and well tolerated.
开始日期2023-09-15 |
申办/合作机构 |
A Double-Blind, Cross-Over Placebo-Controlled and Active-Controlled Trial To Evaluate The Effect Of A Supratherapeutic Dose Of MK-8189 On The QTc Interval In Participants With Schizophrenia
The primary purpose of this study to evaluate the effect of a supratherapeutic dose of 80 mg MK-8189 on the QT interval corrected for heart rate (QTc interval) and to assess the safety and tolerability of multiple once-daily doses of MK-8189 in participants with schizophrenia.
The primary hypothesis is that the administration of an 80 mg MK-8189 dose on Day 2 does not prolong the QTc interval to a clinically significant degree. Specifically, the true mean difference (MK-8189 - placebo) in QTc change from baseline is less than 10 milliseconds (msec).
The primary hypothesis is that the administration of an 80 mg MK-8189 dose on Day 2 does not prolong the QTc interval to a clinically significant degree. Specifically, the true mean difference (MK-8189 - placebo) in QTc change from baseline is less than 10 milliseconds (msec).
开始日期2023-06-26 |
申办/合作机构 |
100 项与 MK-8189 相关的临床结果
登录后查看更多信息
100 项与 MK-8189 相关的转化医学
登录后查看更多信息
100 项与 MK-8189 相关的专利（医药）
登录后查看更多信息
5
项与 MK-8189 相关的文献（医药）2023-08-01·Journal of lipid research
Magnetic resonance imaging detects white adipose tissue beiging in mice following PDE10A inhibitor treatment.
Article
作者: Meng, Xiangjun ; Smith, Sean M ; Harrell, Charles M ; Tomaszewski, Michal R ; Haley, Hyking D ; Mcdonald, Terrence P ; Miller, Corin O
Weight gain is a common harmful side effect of atypical antipsychotics used for schizophrenia treatment. Conversely, treatment with the novel phosphodiesterase-10A (PDE10A) inhibitor MK-8189 in clinical trials led to significant weight reduction, especially in patients with obesity. This study aimed to understand and describe the mechanism underlying this observation, which is essential to guide clinical decisions. We hypothesized that PDE10A inhibition causes beiging of white adipose tissue (WAT), leading to weight loss. Magnetic resonance imaging (MRI) methods were developed, validated, and applied in a diet-induced obesity mouse model treated with a PDE10A inhibitor THPP-6 or vehicle for measurement of fat content and vascularization of adipose tissue. Treated mice showed significantly lower fat fraction in white and brown adipose tissue, and increased perfusion and vascular density in WAT versus vehicle, confirming the hypothesis, and matching the effect of CL-316,243, a compound known to cause adipose tissue beiging. The in vivo findings were validated by qPCR revealing upregulation of Ucp1 and Pcg1-α genes, known markers of WAT beiging, and angiogenesis marker VegfA in the THPP-6 group. This work provides a detailed understanding of the mechanism of action of PDE10A inhibitor treatment on adipose tissue and body weight and will be valuable to guide both the use of MK-8189 in schizophrenia and the potential application of the target for weight loss indication.
2023-01-26·Journal of medicinal chemistry1区 · 医学
Discovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia
1区 · 医学
Article
作者: Ma, Bennett ; Fritzen, Jeff ; Shipe, William D. ; Huszar, Sarah ; Eddins, Donnie ; Smith, Sean M. ; Layton, Mark E. ; Hayes, Robert P. ; Kandebo, Monika ; Fuerst, Joy ; Raheem, Izzat ; Coleman, Paul J. ; Uslaner, Jason M. ; Wollenberg, Gordon K. ; Hartingh, Timothy J. ; McGaughey, Georgia B. ; Li, Jing ; Cox, Christopher D. ; Kern, Jeffrey C.
PDE10A is an important regulator of striatal signaling that, when inhibited, can normalize dysfunctional activity. Given the involvement of dysfunctional striatal activity with schizophrenia, PDE10A inhibition represents a potentially novel means for its treatment. With the goal of developing PDE10A inhibitors, early optimization of a fragment hit through rational design led to a series of potent pyrimidine PDE10A inhibitors that required further improvements in physicochemical properties, off-target activities, and pharmacokinetics. Herein we describe the discovery of an isomeric pyrimidine series that addresses the liabilities seen with earlier compounds and resulted in the invention of compound 18 (MK-8189), which is currently in Phase 2b clinical development for the treatment of schizophrenia.
2022-01-01·Neuroscience and biobehavioral reviews1区 · 心理学
New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics
1区 · 心理学
Review
作者: Kaar, Stephen J ; Whitehurst, Thomas S ; Howes, Oliver D ; Lobo, Maria C
Schizophrenia is associated with substantial unmet needs, highlighting the necessity for new treatments. This narrative review compares the pharmacology, clinical trial data and tolerability of novel medications to representative antipsychotics. Cariprazine, brexpiprazole and brilaroxazine are partial dopamine agonists effective in acute relapse. Lumateperone (serotonin and dopamine receptor antagonist) additionally benefits asocial and depressive symptoms. F17464 (D3 antagonist and 5-HT1A partial agonist) has one positive phase II study. Lu AF35700 (dopamine and serotonin receptor antagonist) was tested in treatment-resistance with no positive results. Pimavanserin, roluperidone, ulotaront and xanomeline do not act directly on the D2 receptor at clinical doses. Initial studies indicate pimavanserin and roluperidone improve negative symptoms. Ulotaront and xanomeline showed efficacy for positive and negative symptoms of schizophrenia in phase II trials. BI 409306, BI 425809 and MK-8189 target glutamatergic dysfunction in schizophrenia, though of these only BI 425809 showed efficacy. These medications largely have favourable cardiometabolic side-effect profiles. Overall, the novel pharmacology, clinical trial and tolerability data indicate these compounds are promising new additions to the therapeutic arsenal.
5
项与 MK-8189 相关的新闻（医药）2024-02-05
·精准药物
2022年期间，关于Fragment to lead 的研究得到了广泛的关注，并产生了许多重要的出版物。其中18 篇文章介绍了已成功片段的先导研究，包括三个临床化合物（MTRX1719、MK-8189 和 BI-823911）的开发。Andrew J. Woodhead等人以表格形式总结了2022年发表的基于片段的药物发现的相关文章，并讨论了其在2015-2022年的综合案例的特征，如靶点类别、筛选方法和配体效率，跟踪该领域进展。引言基于片段的药物发现（FBDD）是目前研究药物靶点和鉴定多类靶点先导化合物的一种行之有效的方法。FBDD 大致包括两个步骤：(1) 使用检测弱亲和力的优化技术筛选低分子量、低复杂度分子（"片段"）库（产生 "命中"）；(2) 通常在结构和计算方法的指导下进行合理设计，以优化这些命中，从而提高药效和分子特性（产生 "先导"）。迄今为止，FBDD 已开发出 7 种已获批准的药物，50 多种片段衍生化合物已进入临床开发阶段，其中 40% 已获批准或正在进行试验（表 1）。表 1. 片段衍生的已获批准药物和 2、3 期临床开发化合物作者根据以下标准对所收到的文章进行了评估，符合标准的例子见表 2：命中片段的分子量 (MW) < 300。所发现的片段来自筛选（如生物测定、生物物理方法、X 射线、虚拟筛选或它们的任何组合）或已知配体的解构。先导物的效力/亲和力等于或优于 2 μM。从片段到先导物的效力/亲和力至少提高 100 倍。文章的发表日期（根据主要引文定义）在 2022 日历年内。表 2. 2022 年片段转化为先导药物的论文概览目标靶点类别下图1显示了 "F2L视角 "每年的目标类别分布情况（以及所有八年的总分布情况）。迄今为止，共有198个目标类别，其中最普遍的目标类别分别是其他酶（70个）、激酶（49个）和其他蛋白质-蛋白质相互作用（PPIs）（30个）。2022 年，PPIs 和非激酶或蛋白酶类是最大的类别（合计占 80%），与往年相比，溴链（6%）、激酶（5%）和其他（5%）只占很小的比例。图 1. 成功的 F2L 案例研究针对的蛋白质类别Kinases激酶Kinases历来占总分布的四分之一。今年的减少可能是由于数据集较小，存在自然变异。以前在文献中报道过的与蛋白激酶 A（PKA）已知实验结合模式的片段被用作模板，利用 Enamine REAL 数据库构建和对接枚举库。在一个优化周期内，后续合成得到的先导化合物的效力提高了 13,500 倍。这种趋势是否会持续下去，我们拭目以待。GPCR表 2 中没有 G 蛋白偶联受体（GPCR）的例子，不过，也有一些不完全符合标准的例子值得一提。其中一个例子是，Shepherd 等人利用表面等离子体共振（SPR）筛选技术确定了一系列腺苷受体家族成员的片段结合亲和力，并开展了后续工作以评估其功能后果。在第二项研究中，对 5HT2A 受体进行了筛选，确定了低 μM 大小的片段，并将其进一步优化到 100 nM 以下，从而以微弱差距未达到表 2 的纳入标准。Proteases蛋白酶抑制剂Proteases占11%，而2021年为0%（但与8%的总平均值一致）。有趣的是，这两个条目（2 和 3）都采用了虚拟筛选的方法来寻找新药，与蛋白激酶 A 的例子类似，这或许说明了人们对这类酶的结合了解的越来越多。具体来说，HIV-1蛋白酶几十年来一直是药物治疗的靶点，而SARS CoV-2 Mpro也受到了广泛关注，这导致了针对这种病毒蛋白酶的药物Paxlovid的快速发展。Other Enzymes其他酶的抑制剂占比44%，略高于全球平均水平（35%）。表 2 的这一部分包括两个临床候选药物：MRTX1719（条目 6），针对 PRMT5 的一种非活性形式，其先导化合物的效力比起始片段高出 8 个数量级；MK-8189（条目 10），是一种磷酸二酯酶 10 A 抑制剂。条目 4 描述了将一个命中片段的特征与一个相关分子合并，从而产生了一种针对 NDM-1 和其他金属-β-内酰胺酶的先导化合物。苯基吡唑[等温滴定量热法（ITC）测定的 Kd = 2.88 mM]，通过结构引导优化，该片段被优化为 3.6 μM 的先导物，配体效率大大提高。PPIs2022年，在PPI领域有几个值得一提的例子。Shishodia 及其合作者描述了针对 PBRM1-BD2 的 2000 个片段的蛋白质检测 NMR 筛选，并将结合最紧密的片段系列优化为具有选择性、细胞活性的化学探针。第二个值得注意是开发了调控枢纽蛋白14-3-3 的 PPI 稳定剂。利用时间分辨 FRET 分析法，研究人员确定了一种能增强 14-3-3 二聚化并导致蛋白结合增加的药物。迄今为止，大多数实例都是 PPI 抑制剂，而 Venetoclax 的开发是一个重要的片段衍生成功案例（表 1）。稳定与生理相关的 PPI 或诱导新的 PPI 与泛素连接酶系统的成分构成了靶向蛋白质降解的基础。Covalent Inhibitors2022年发表的不符合表2标准的其他基于片段的论文采用了共价方法。St. Denis 等人描述了一个亲电片段库的设计，该库利用 X 射线晶体学筛选法针对 ERK2 进行筛选。发现了多个以 ATP 结合位点附近的 Cys166 为靶点的片段，并对其中一个片段进行了优化，以产生低 μM 的先导物。Yoshimori 等人开发了一种生成式人工智能模型（DeepSARM），用于开发共价激酶抑制剂，并以酪氨酸激酶（BTK）为例，对新设计的配体进行评估。13 和 16 强调了 FBDD 在共价药物发现中的持续应用（13，图 2），针对 KRASG12C，从一个非共价片段开始，在引入亲电子体之前最大化非共价相互作用。图 2. 针对 KRASG12C（表 2 中的13）的片段-引线优化。通过蛋白质观察核磁共振筛选确定了一个非共价片段。在加入共价弹头之前进行了结构指导优化。片段筛查方法图 4 显示了表 2 中列出的 F2L 活动中使用的筛查方法，并将其与往年和所有分析年份的总数进行了比较。此外，研究人员还能针对 PRMT5-SAM 进行 SPR 反筛选，以确认这些片段能如愿与 PRMT5-MTA 发生优先结合。图 4：（A）过去 8 年成功的 F2L 案例研究中使用的碎片筛选技术。(B) 饼图按 2022 栏所占百分比分列。2022 年的几项研究报告了很有前景的新片段筛选技术，这些技术可以发现新靶点，但没有进行大量的靶点优化工作，因此不符合表 2 的收录标准。有趣的例子有：利用DNA编码片段的光激活共价捕获（PAC-FragmentDEL）发现针对PAK4和2-表聚酶的靶点；纳米液体毛细管色谱法鉴定乙酰胆碱酯酶抑制剂；利用多肽荧光探针进行溶解变色蛋白结合测定；利用本机质谱鉴定破坏HSP90-HOP蛋白-蛋白相互作用的片段。寻找命中策略在研究14中，生化检测、热熔融和 SPR 被结合使用，虽然这些技术之间的重叠程度很低，但研究人员认为，应用正交检测可以最大限度地降低漏检的风险，这些漏检的结果随后会被纳入 X 射线晶体学进行结构指导优化。马丁等人在一篇论文中也提到了正交技术的使用，他们认为通过 "三角测量 "的方法可以最好地实现新药的验证和优先排序，相比之下，项目 1 采用的是 "晶体结构优先 "策略，而不是对片段进行任何预筛选。他们最初发现的是与 PKA 结合的弱片段的 X 射线晶体结构，然后利用这些晶体结构进行虚拟筛选，以确定类似先导化合物。片段库FBDD 的一个重要因素是设计合适的片段库。片段库的规模从 100 个到 13 000 个片段不等，规模较大的片段库通常通过核磁共振进行筛选。Enamine Real 和药明康德 GalaXi 等超大型枚举化学库的出现，已成为药物发现界进行初筛、跟踪和虚拟筛选的宝贵资源；预计其使用量在未来几年将显著增加。还有一类是使用虚拟化合物作为主要筛选来源的作品。今年，使用这种方法的作品数量有所增加（2022 年为 13%，而历史平均水平为 8%），分别筛选了 350 万、2.35 亿和 1.28 万个片段。片段优化片段的确定只是优化过程的开始。要将片段进化成更强效的先导分子往往非常具有挑战性。大约 50% 的实例报告了虚拟筛选或对接协议的使用，使用物理学的计算方法进行片段优化也未来可期。如相对自由能扰动和绝对自由能扰动（FEP），尤其是在与实验得出的结构信息相结合时。这些技术已成功应用于后期的 "从先导到先导"（hit-to-lead）和 "先导优化"（lead optimization）计划中；然而，片段的挑战依然存在。在分子动力学模拟过程中，片段大小的化合物的结合模式并不能保证保持不变。总结2022年，FBDD领域取得了一些显著成就，包括针对突变型KRAS的非共价命中物优化、针对RNA靶点的片段筛选和优化以及利用片段筛选整个SARS-Cov-2蛋白质组。FBDD 已开始用于 PPI 稳定化和靶向蛋白降解（PAK1 降解剂）；预计这一趋势将继续下去。未来 FBDD 的发展领域可能是利用 DNA 编码的定点文库进行快速片段命中跟踪，以及将低温电子显微镜用于 FBDD 以实现新的靶标类别。我们期待着这一领域的发展以及 FBDD 在为患者提供小分子疗法方面的持续影响。参考文献：https://doi-org.libproxy1.nus.edu.sg/10.1021/acs.jmedchem.3c02070声明：发表/转载本文仅仅是出于传播信息的需要，并不意味着代表本公众号观点或证实其内容的真实性。据此内容作出的任何判断，后果自负。若有侵权，告知必删！长按关注本公众号 粉丝群/投稿/授权/广告等请联系公众号助手 觉得本文好看，请点这里↓
上市批准
2023-05-16
The psychosis in Parkinson's and Alzheimer's disease market size shall grow during the forecast period (2023–2032). This increase will be due to rising disease awareness and improving diagnosis, besides the launch of emerging therapies by key companies, including Sunovion Pharmaceuticals, Karuna Therapeutics, Vanda Pharmaceuticals, and others.
LAS VEGAS, May 16, 2023 /PRNewswire/ -- DelveInsight's
Psychosis in Parkinson's and Alzheimer's Disease Market Insights report includes a comprehensive understanding of current treatment practices, psychosis in Parkinson's and Alzheimer's disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Psychosis in Parkinson's and Alzheimer's Disease Market Report
As per DelveInsight analysis, the psychosis in Parkinson's and Alzheimer's disease market size in the 7MM was approximately
USD 1.2 billion in 2022.
According to the assessment done by DelveInsight, the estimated total diagnosed prevalent psychosis in Parkinson's and Alzheimer's disease cases in the 7MM were approximately
6.7 million in 2022.
Leading psychosis in Parkinson's and Alzheimer's disease companies such as
Sunovion Pharmaceuticals, Karuna Therapeutics, Vanda Pharmaceuticals, Suven Life Sciences, Enterin, Intra-Cellular Therapies, Merck Sharp & Dohme, and others are developing novel psychosis in Parkinson's and Alzheimer's disease drugs that can be available in the psychosis in Parkinson's and Alzheimer's disease market in the coming years.
The promising psychosis in Parkinson's and Alzheimer's disease therapies in the pipeline include
Ulotaront (SEP-363856), KarXT (xanomeline-trospium), FANAPT (iloperidone), Masupiridine (SUVN-502), ENT-01, ITI-1284, MK-8189
, and others.
Discover which therapies are expected to grab the major psychosis in Parkinson's and Alzheimer's disease market share @
Psychosis in Parkinson's and Alzheimer's Disease Market Report
Psychosis in Parkinson's and Alzheimer's Disease Overview
Psychosis is a group of symptoms that affect the mind and indicate a loss of contact with reality. Individuals' ideas and perceptions are altered during a psychotic episode, making it difficult to distinguish between what is genuine and what is not. In Parkinson's disease and Alzheimer's disease, both exogenous and endogenous factors contribute to the development of psychosis. Old age, sleep difficulties, long-term neurodegenerative conditions, depression, cognitive impairment, and vision abnormalities are all risk factors for the disease.
Parkinson's disease psychosis (PDP) is a prevalent occurrence in Parkinson's disease patients that is associated with significant morbidity and mortality. It is caused by anomalies in dopamine, serotonin, and glutamate neurotransmission induced by Lewy body deposition in the brain. Alzheimer's disease psychosis (ADP), which is common in Alzheimer's disease patients, is caused by increased excitatory neuron sensitivity and post-transcriptional mechanisms that alter synaptic protein in the brain. Due to the complexity of the aetiologies and physiological hypotheses, many diagnostic techniques, including neuroimaging, neurophysiological, genotypic, and serologic examinations, are used to diagnose psychosis in Parkinson's and Alzheimer's disease patients.
Psychosis in Parkinson's and Alzheimer's Disease Epidemiology Segmentation
DelveInsight estimates that there were approximately
6.7 million diagnosed prevalent cases of psychosis in Parkinson's and Alzheimer's disease in the 7MM in 2022.
Among the 7MM, the US contributed to the largest diagnosed prevalent psychosis population in Parkinson's and Alzheimer's disease, acquiring
~34% in 2022. In contrast, the UK accounted for the least, with approximately
4% of the total population share in 2022.
The psychosis in Parkinson's and Alzheimer's disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
Total diagnosed prevalent cases of Parkinson's and Alzheimer's disease
Age-specific cases of Parkinson's and Alzheimer's disease
Gender-specific cases of Parkinson's and Alzheimer's disease
Total diagnosed prevalent cases of Psychosis in Parkinson's and Alzheimer's disease
Psychosis in Parkinson's and Alzheimer's Disease Treatment Market
The current treatment of psychosis in Parkinson's and Alzheimer's disease includes both nonpharmacological and pharmacological treatments. The major goal of psychosis in Parkinson's and Alzheimer's disease treatment is to lessen the frequency and severity of psychotic symptoms while causing little worsening of motor symptoms. The use of conventional and atypical antipsychotics (e.g., aripiprazole, clozapine, quetiapine, and others) is the first-line treatment. However, atypical antipsychotics are frequently chosen in the initial therapy, which minimizes the likelihood of further worsening in patients. Aside from
antipsychotics,
5-HT3 receptor antagonists, acetylcholinesterase inhibitors (donepezil, rivastigmine), and various antidepressants are utilized. While cognitive behavioral therapy (CBT), reasoning, and rehabilitation are used to reduce behavioral and psychological symptoms of dementia (BPSD), anxiety, psychosis, agitation, aggression, sleep difficulties, and other symptoms linked with psychosis in Parkinson's and Alzheimer's disease.
The US FDA has approved
ACADIA's NUPLAZID (pimavanserin), a receptor antagonist (5-HT2A, 5-HT2C), for the treatment of hallucination and delusion associated with psychosis in Parkinson's disease patients. It is the only approved therapy available in the US. Recent trials also suggest that the medicine is helpful in Alzheimer's disease patients with more severe psychosis. At the same time, more long-term studies are needed to define better the efficacy and long-term safety profile of pimavanserin for treating psychosis in Alzheimer's disease. Though the expensive cost of pimavanserin certainly restricts its use, the findings in Parkinson's disease psychosis patients and evidence from Alzheimer's disease trials are convincing.
There are currently no approved medicines for Alzheimer's disease psychosis patients; the major treatment is antipsychotics. Off-label therapies that are routinely utilized include
quetiapine, clozapine, risperidone, aripiprazole, citalopram, and escitalopram. Aripiprazole has been shown in clinical tests to be effective and safe. In contrast, citalopram has been shown to be useful in lowering agitation and the severity of hallucinations and delusions in Alzheimer's disease psychosis patients.
To know more about psychosis in Parkinson's and Alzheimer's disease treatment guidelines, visit @
Psychosis in Parkinson's and Alzheimer's Disease Management
Psychosis in Parkinson's and Alzheimer's Disease Pipeline Therapies and Key Companies
Ulotaront (SEP-363856): Sunovion Pharmaceuticals
KarXT (xanomeline-trospium): Karuna Therapeutics
FANAPT (iloperidone): Vanda Pharmaceuticals
Masupiridine (SUVN-502): Suven Life Sciences
ENT-01: Enterin
ITI-1284: Intra-Cellular Therapies
MK-8189: Merck Sharp & Dohme
Learn more about the FDA-approved drugs for psychosis in Parkinson's and Alzheimer's disease @
Drugs for
Psychosis in Parkinson's and Alzheimer's Disease Treatment
Psychosis in Parkinson's and Alzheimer's Disease Market Dynamics
The psychosis in Parkinson's and Alzheimer's disease market dynamics are anticipated to change in the coming years due to
increasing awareness and improved diagnosis. Increased awareness and a better understanding of disease pathogenesis have improved diagnosis and treatment. Moreover, the recent
FDA approval of NUPLAZID, the first approved therapy for treating hallucinations and delusions associated with Parkinson's disease psychosis, suggests a positive shift in the psychosis in Parkinson's and Alzheimer's disease market. Furthermore, pharma companies have an opportunity to develop
therapies with enhanced safety and tolerability profiles, effectively lowering symptoms and preventing the recurrence of psychosis in Parkinson's and Alzheimer's disease. In addition, the
advancement of biomarkers for cognitive impairment enables exact diagnosis and individualized therapy.
However, several factors are impeding the growth of psychosis in the Parkinson's and Alzheimer's disease market. Psychosis in Parkinson's disease and Alzheimer's disease is related to
low quality of life, higher healthcare resource utilization, and a significant
economic burden.
NUPLAZID and the other atypical
antipsychotics recommended for treatment include black box warnings and adverse effects. Moreover, a
lack of a medication development pipeline, the
ongoing use of antipsychotics despite the hazards, and a lack of specialized nonpharmacological interventions may cause a dip in the growth of psychosis in the Parkinson's and Alzheimer's disease market. Furthermore, there is a
high attrition rate when drug development proceeds from first-in-human trials to pivotal registration studies due to a lack of efficacy. Hence all these factors may hamper the psychosis in Parkinson's and Alzheimer's disease market growth in the coming years.
Scope of the
Psychosis in Parkinson's and Alzheimer's Disease
Market Report
Therapeutic Assessment: Psychosis in Parkinson's and Alzheimer's Disease current marketed and emerging therapies
Psychosis in Parkinson's and Alzheimer's Disease
Market Dynamics: Attribute Analysis of Emerging Psychosis in Parkinson's and Alzheimer's Disease Drugs
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Psychosis in Parkinson's and Alzheimer's Disease Market Access and Reimbursement
Discover more about psychosis in Parkinson's and Alzheimer's disease drugs in development @
Psychosis in Parkinson's and Alzheimer's Disease Clinical Trials
Table of Contents
Related Reports
Parkinson's Disease Psychosis Pipeline
Parkinson's Disease Psychosis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Parkinson's disease psychosis companies, including
Vanda Pharmaceuticals, Sumitomo Pharma, among others.
Psychosis Market
Psychosis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key psychosis companies, including
Teva Pharmaceutical Industries Ltd., Amgen Inc., Pfizer Inc., Novartis International AG., Merck & Co. Inc., Sanofi S.A., among others.
Parkinson's Disease Psychosis Market
Parkinson's Disease Psychosis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson's disease psychosis companies, including
Vanda Pharmaceuticals, Sumitomo Pharma, among others.
Alzheimer's Disease Market
Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Alzheimer's disease companies, including
AZTherapies, Cerecin, Neurotrope, Lyndra, AC Immune, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
.
Contact Us
Shruti Thakur
[email protected]
+1(919)321-6187
Logo:
SOURCE DelveInsight Business Research, LLP
上市批准
2022-12-20
DUBLIN--(
BUSINESS WIRE
)--The
"Alzheimer's Disease Therapeutics (2022 Edition) - Market Insight, Epidemiology and Pipeline Assessment (By Molecule Type, By Route of Administration, By Pipeline Phase)"
report has been added to
ResearchAndMarkets.com's
offering.
Alzheimer's disease Therapeutics Pipeline Analysis has 101 active drugs undergoing several stages of clinical trials.
The Alzheimer's disease Therapeutics Pipeline is driven by an increasing gap of unmet need of effective therapeutics that can cure Alzheimer's disease. Additionally, life expectancy has increased due to various healthcare reforms in major economies such as the U.S., Japan, and China. This has resulted in a large geriatric population which is the age group most affected by the disease.
Alzheimer's prevalence is rising rapidly and despite decades of research, the disease remains incurable. The majority of therapeutics target symptom reduction and slowing the progression of the disease. The Food and Drug Administration (FDA) approved aducanumab (Aduhelm) for the treatment of certain cases of Alzheimer's disease in June 2021 and this is the first drug approved for Alzheimer's disease in decades.
Eisai, Biogen, Hoffmann-La Roche, AZTherapies, Cerecin, Neurotrope, AC Immune, Cassava Sciences, AB Science, Anavex Life Sciences, Athira Pharma, Denali Therapeutics Inc., and other notable companies are developing therapeutic candidates to improve the Alzheimer's Diagnosis and treatment scenario.
Scope of the Report
The report analyses the Alzheimer's Disease Therapeutics in Pipeline by Molecule Type (Small Molecules, Monoclonal Antibody, Vaccine, DNA/RNA Based, Natural products, Gene Therapy, Cell Therapy, Others).
The report analyses the Alzheimer's disease Therapeutics by Route of Administration (Oral, Intravenous, Intramuscular, Subcutaneous, Intrathecal, Intranasal, Other).
The report analyses the Alzheimer's disease Therapeutics by Pipeline Phase (Phase I, Phase I/II, Phase II, Phase II/III, Phase III, Phase IV, Preclinical).
The report analyses the Pain Management Drugs Market by Availability (Over the Counter (OTC), Prescription).
The Alzheimer's Disease Therapeutics Pipeline Analysis has been analysed By Region (Americas, Europe, Asia Pacific, and MEA).
The Global Pain Management Drugs Market has been analysed By Region (Americas, Europe, Asia Pacific, and MEA).
The key insights of the report have been presented through the leading company shares.
Also, the major, trends, drivers and challenges as well as Unmet Needs of the industry has been analysed in the report.
The companies analysed in the report include Eli-Lily & Co , Elsal Co., Ltd., BioVie, Johnson and Johnson, Otsuka Pharmaceutical Co., Ltd. H. Lundbeck A/S, Novartis, Cognition Therapeutics, Merck Sharp & Dohme LLC, Biogen.
Key Target Audience
Alzheimer's Disease Therapeutics Companies
End Users (Hospitals and clinics)
Research and Development (R&D) Organizations
Government Bodies & Regulating Authorities
Investment Banks and Equity Firms
Key Topics Covered:
1. Introduction
1.1 Alzheimer's Disease Therapeutics Overview
1.2 Scope of Research
2. Executive Summary
2.1 Market Dashboard
2.2 Regional Insights
2.3 Market Ecosystem Factors
3. Research Methodology
3.1 Data Collection Process
3.2 Market Size Calculation-Top-to-Bottom
4. Macro Economic Indicator Outlook
4.1 Global, Region wise GDP Growth
4.2 Global Medical Spending
4.3 Current Healthcare Expenditure
4.4 Pharmaceutical Spending/capita
5. Competitive Positioning
5.1 Companies' Product Positioning
5.2 Competitive positioning
5.2.1 Eli-Lily & Co
5.2.2 Elsal Co., Ltd.
5.2.3 BioVie
5.2.4 Johnson & Johnson
5.2.5 Otsuka Pharmaceutical Co., Ltd.
5.2.6 H. Lundbeck A/S
5.2.7 Novartis
5.2.8 Cognition Therapeutics
5.2.9 Merck Sharp & Dohme LLC
5.2.10 Biogen
6. Alzheimer's disease background
6.1 AD Fact Sheet
6.2 Epidemiology
6.3 Causes and Risk Factors
6.4 Diagnosis and Assessment
6.5 Unmet Needs
7. Therapeutics in Pipeline
7.1 Pipeline Scenario
7.2 Alzheimer's Therapeutics Comparative Review
8. Pipeline Analysis
9. Phase I therapeutics Overview
9.1 LY3372993
9.1.1 Drug Description
9.1.2 Outcomes
9.2 Lu AF87908
9.3 anle138b
9.4 ASN51
9.5 CMS121
9.6 IBC-Ab002
9.7 LX1001
9.8 MK-2214
9.9 MK-8189
9.10 ACU193
9.11 NIO752
9.12 ALN-APP
9.13 TB006
9.14 SNK01
9.15 Pepinemab
9.16 GB-5001
9.17 AC-1202
9.18 SHR-1707
9.19 BEY2153
9.20 JNJ-40346527
9.21 APNmAb005
9.22 NPT 2042
9.23 ALZ-101
10. Phase I/II therapeutics Overview
10.1 Posiphen
10.1.1 Drug Description
10.1.2 Outcomes
10.1.3 Collaborators
10.2 PrimeProT/ PrimeMSKT
10.3 TB006
10.4 RO7126209
10.5 DNL593
10.6 BIIB080
10.7 E2814
10.8 Tdap
10.9 ACI-35.030/ JACI-35.054
10.10 ACI-24.060
10.11 IVL3003
11. Phase II therapeutics Overview
11.1 Lecanemab
11.1.1 Drug Description
11.1.2 Outcomes
11.1.3 Collaborators
11.2 Lomecel-B
11.3 AL002
11.4 AL001
11.5 CT1812 (Elaya)
11.6 APH-1105
11.7 ATH-1017
11.8 T-817MA
11.9 Montelukast buccal film
11.10 ABBV-916
11.11 Bepranemab
11.12 TB006
11.13 LY3372689
11.14 MW150
11.15 EX039
11.16 JNJ-42847922
11.17 REM0046127
11.18 Bryostatin 1
11.19 NanoLithium NP03
11.20 AstroStem
11.21 Gantenerumab
11.22 Semorinemab
11.23 Obicetrapib
11.24 ALZ-801
11.25 CY6463
11.26 Crenezumab
11.27 T3D-959
11.28 PMZ-1620
11.29 GV1001
11.30 ACZ885
11.31 PQ912
11.32 APH-1105
11.33 SLS-005
11.34 Flos gossypii flavonoids
11.35 Human Mesenchymal Stem cells (MSCs)
11.36 JNJ-63733657
11.37 IGC-AD1
11.38 TW001
11.39 ABvac40
12. Phase II/III therapeutics Overview
12.1 Tricaprilin
12.1.1 Drug Description
12.1.2 Outcomes
12.2 ANAVEX2-73
12.3 Piromelatine
12.4 AGB101
13. Phase III therapeutics Overview
13.1 Simufilam
13.1.1 Drug Description
13.1.2 Outcomes
13.1.3 Collaborators
13.2 ATH-1017
13.3 Lecanemab
13.4 Nilotinib BE
13.5 Brexpiprazole
13.6 Masitinib
13.7 Remternetug
13.8 Donanemab
13.9 NE3107
13.10 Gantenerumab
13.11 GV-971
13.12 Aducanumab
13.13 TRx0237
13.14 Semagludtide
13.15 BPDO-1603
13.16 AR1001
13.17 KarXT
13.18 AXS-05
14. Phase IV therapeutics Overview
14.1 Choline Alfoscerate
14.1.1 Drug Description
14.1.2 Outcomes
14.2 Ebicomb
14.3 Rivastigmine
14.4 GV-971
15. Preclinical Phase therapeutics Overview
15.1 PMN310
15.1.1 Drug Description
15.1.2 Outcomes
15.1.3 Collaborators
15.2 PRX123
16. Pipeline analysis, By molecule type
16.1 Alzheimer's Therapeutics Comparative Review, by Molecule type
17. Pipeline analysis, By Route of Administration
17.1 Alzheimer's Therapeutics Comparative Review, By Route of Administration
For more information about this report visit
https://www.researchandmarkets.com/r/wcw7f7
上市批准临床2期临床1期
100 项与 MK-8189 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性精神分裂症 | 临床2期 | 美国 | 2017-03-08 | |
| 躁郁症1型 | 临床1期 | 美国 | 2024-04-08 | |
| 攻击 | 临床1期 | 美国 | 2022-07-01 | |
| 躁动 | 临床1期 | 美国 | 2022-07-01 | |
| 阿尔茨海默症 | 临床1期 | 美国 | 2022-07-01 | |
| 精神障碍 | 临床1期 | 美国 | 2022-07-01 | |
| 肝病 | 临床1期 | 美国 | 2021-03-17 | |
| 精神分裂症 | 临床1期 | - | 2014-08-05 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床1期 | 14 | (Moderate Hepatic Impairment Participants) | 廠憲範製壓遞膚窪憲淵(醖壓範鹽壓夢膚獵簾範) = 鬱鏇艱壓選淵蓋淵簾獵 選蓋築艱襯獵構衊糧鏇 (觸憲築遞夢網網鏇餘衊, 醖鏇膚壓鹹鹹夢願餘願 ~ 鏇鏇蓋廠廠網製糧夢襯) 更多 | - | 2023-10-06 | ||
(Healthy Participants) | 廠憲範製壓遞膚窪憲淵(醖壓範鹽壓夢膚獵簾範) = 艱鏇願積廠網鬱夢築齋 選蓋築艱襯獵構衊糧鏇 (觸憲築遞夢網網鏇餘衊, 鬱糧膚艱憲願憲膚襯壓 ~ 鑰餘衊繭膚範鹽糧糧鹽) 更多 | ||||||
临床2期 | 224 | Placebo matching risperidone+MK-8189 (MK-8189) | 衊淵鹹夢選鹹膚觸顧積(築醖襯遞遞廠鏇製願壓) = 網蓋獵艱鹽繭廠壓糧糧 網壓憲糧醖壓範膚鑰繭 (選壓鹽遞糧蓋憲夢積構, 鬱膚糧廠選網襯鬱餘築 ~ 廠選網選範壓鑰鹹鏇築) 更多 | - | 2018-12-26 | ||
risperidone+Placebo matching MK-8189 (Risperidone) | 衊淵鹹夢選鹹膚觸顧積(築醖襯遞遞廠鏇製願壓) = 廠襯淵憲鏇醖鬱齋壓齋 網壓憲糧醖壓範膚鑰繭 (選壓鹽遞糧蓋憲夢積構, 憲網簾顧獵餘廠鹹鑰願 ~ 繭築獵製鏇夢糧膚簾醖) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
标准版
¥16800
元/账号/年
新药情报库 ｜ 省钱又好用！
立即使用
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用